Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program are key focus areas for potential healthcare reforms.Goldman Sachs analyst Salveen Richter, however, warns that federal Medicaid cuts could lead to stricter policies and lower drug coverage.Per Richter, the 340B program is currently facing increased scrutiny, with proposed reforms that could potentially benefit biopharma companies by limiting eligibility for drug discounts, which w ...